INMED PHARMACEUTICALS INC. Finance Lease, Liability, to be Paid, Year Three
INMED PHARMACEUTICALS INC. (INM) had Finance Lease, Liability, to be Paid, Year Three of $1.10 million as of 2023-12-31, per its 10-Q filed 2024-02-13.
Discontinued › Notes › Commitment and Contingencies
us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree · last filed 2024-02-13
- 2023-12-31: Finance Lease, Liability, to be Paid, Year Three $1.10M.
| Period end | Finance Lease, Liability, to be Paid, Year Three |
|---|---|
| 2023-12-31 | $1.10M 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |